多发性骨髓瘤的预后分层及分层治疗进展
摘要
多发性骨髓瘤（multiplemyeloma，MM）是以骨髓中浆细胞克隆性增生，并分泌单克隆球蛋白为特征的一种恶性肿瘤。尽管近十年来新药的应用使骨髓瘤预后显著改善，但不同患者在疾病进程、治疗反应和生存期上仍显示出很大的异质性。
出处
《临床血液学杂志》
CAS
2013年第6期743-746,共4页
Journal of Clinical Hematology
参考文献20
-
1LUDWIG H, BOLE] ACK V, CROWLEY r. et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma[J].] Clin Oncol , 2010,28: 1599-1605. 被引量：1
-
2AVET-LOISEAU H, ATTAL M, MOREAU p, et al, Genetic abnormalities and survival in multiple my?eloma: the experience of the Intergroupe Francophone du Myelome[J]. Blood, 2007,109: 3489 - 3495. 被引量：1
-
3GUTIERREZ N C,CASTELLANOS M V,MARTIN M L, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t (4; 14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis[J]. Leukemia, 2007 ,21: 143- 150. 被引量：1
-
4SAN MIGUEL] F,SCHLAG R,KHUAGEVA N K, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma[J]. N EnglJ Med,2008, 359: 906- 917. 被引量：1
-
5MIKHAEL] R, DINGLI D, ROY V, et al. Manage?ment of newly diagnosed symptomatic multiple mye?lorna: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013[J]. Mayo Clin Proc,2013,88:360- 376. 被引量：1
-
6AVET-LOISEAU H,LELEU X,ROUSSEL M,et al. Bortezomib plus dexamethasone induction improves outcome of patients with t (4; 14) myeloma but not outcome of patients with del(17p)[J].J Clin Oncol , 2010,28: 4630-4634. 被引量：1
-
7SHAUGHNESSYJ DJR,ZHAN F ,BURINGTON B E, et al. A validated gene expression model of high?risk multiple myeloma is defined by deregulated ex?pression of genes mapping to chromosome 1[J]' Blood, 2007,109: 2276- 2284. 被引量：1
-
8MOREAU P,ATTAL M,GARBAN F,et al. Hetero?geneity of t (4; 14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem trans?plantation in IFM99 trials[J]. Leukemia, 2007,21: 2020-2024. 被引量：1
-
9KUMAR S,FONSECA R,KETTERLING R P,et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics[J]. Blood, 2012, 119: 2100- 2105. 被引量：1
-
10DURIE B G,SALMON S E. A clinical staging system for multiple myeloma. Correlation of measured mye?loma cell mass with presenting clinical features, re?sponse to treatment, and survival[J]. Cancer, 1975, 36: 842 - 854. 被引量：1
-
1纪冬梅.沙利度胺联合化疗治疗多发骨髓瘤临床分析[J].中国社区医师（医学专业）,2011,13(10):193-194. 被引量：1
-
2吕鸣,吕有灵,王磊,孔宪涛.不同临床期多发性骨髓瘤患者骨髓瘤克隆IgH基因重排研究[J].武警医学,1998,9(6):311-313. 被引量：3
-
3张立明,周梅,金碧琳,唐伟兰,杨玉红,邱迪,楮奕,潘奇群,傅春兰,王晓英.改良VCTD方案治疗老年多发性骨髓瘤15例临床疗效观察[J].临床血液学杂志,2013,26(6):798-799.
-
4多发性骨髓瘤[J].现代临床医学生物工程学杂志,1999,5(3):229-231.
-
5唐尚权,刘风琼,余涛,陈涛,敖华,赵有芳.以骨折为首发表现的骨髓瘤门诊漏诊16例分析[J].中国误诊学杂志,2008,8(1):117-118. 被引量：2
-
6耿传营,陈文明.新药时代初治多发性骨髓瘤患者临床获益与方案选择[J].中华血液学杂志,2013,34(4):297-298. 被引量：1
-
7梅振华,周丽萍,邹亮.多发性骨髓瘤并双侧卵巢浆细胞瘤1例[J].内科急危重症杂志,2012,18(5):317-318. 被引量：1
-
8高大,肖镇.血红蛋白和β2-MG及LDH对多发性骨髓瘤预后影响[J].内蒙古医学杂志,2013,45(1):92-93. 被引量：5
-
9安利,朱琳,补娟,张晓燕,富玲,王晓敏.21例伴髓外浸润的多发性骨髓瘤患者临床特征分析[J].中华临床医师杂志（电子版）,2016,10(11):99-100.
-
10黄海汛,范海泉,陈铭,杨帆,刘江川.经皮椎体成形术治疗多发性骨髓瘤的临床疗效[J].脊柱外科杂志,2014,12(2):100-102. 被引量：4
